Sector Gamma AS Invests $31.48 Million in Pfizer Inc. (NYSE:PFE)

Sector Gamma AS acquired a new position in shares of Pfizer Inc. (NYSE:PFE) during the fourth quarter, Holdings Channel reports. The institutional investor acquired 1,093,416 shares of the biopharmaceutical company’s stock, valued at approximately $31,479,000. Pfizer comprises 7.6% of Sector Gamma AS’s portfolio, making the stock its 2nd largest position.

Other large investors have also modified their holdings of the company. Adage Capital Partners GP L.L.C. lifted its stake in Pfizer by 40.5% during the third quarter. Adage Capital Partners GP L.L.C. now owns 4,739,672 shares of the biopharmaceutical company’s stock worth $157,215,000 after purchasing an additional 1,365,295 shares during the last quarter. LifePlan Financial LLC acquired a new position in Pfizer during the fourth quarter worth $255,000. Brookstone Capital Management grew its holdings in Pfizer by 88.5% during the third quarter. Brookstone Capital Management now owns 452,352 shares of the biopharmaceutical company’s stock worth $14,109,000 after acquiring an additional 212,369 shares during the period. ETF Store Inc. grew its holdings in Pfizer by 12.0% during the third quarter. ETF Store Inc. now owns 6,803 shares of the biopharmaceutical company’s stock worth $214,000 after acquiring an additional 727 shares during the period. Finally, KLCM Advisors Inc. grew its holdings in Pfizer by 75.0% during the fourth quarter. KLCM Advisors Inc. now owns 173,793 shares of the biopharmaceutical company’s stock worth $5,004,000 after acquiring an additional 74,487 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Ratings Changes

PFE has been the topic of a number of research analyst reports. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 target price on shares of Pfizer in a research report on Monday, April 15th. Argus downgraded Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. TD Cowen downgraded Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 target price on the stock. in a research report on Thursday, January 4th. Finally, Guggenheim began coverage on Pfizer in a research report on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. Eleven research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, Pfizer presently has a consensus rating of “Hold” and an average target price of $36.33.

Pfizer Trading Up 0.6 %

NYSE PFE traded up $0.14 during trading hours on Friday, hitting $25.40. 46,526,457 shares of the company’s stock were exchanged, compared to its average volume of 34,120,812. The business’s 50 day moving average is $26.96 and its 200-day moving average is $28.42. Pfizer Inc. has a 12-month low of $25.20 and a 12-month high of $40.37. The firm has a market capitalization of $143.83 billion, a P/E ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to the consensus estimate of $14.37 billion. During the same period in the prior year, the business posted $1.14 earnings per share. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. As a group, analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Investors of record on Friday, May 10th will be given a dividend of $0.42 per share. The ex-dividend date of this dividend is Thursday, May 9th. This represents a $1.68 annualized dividend and a yield of 6.61%. Pfizer’s dividend payout ratio (DPR) is presently 466.67%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.